Pathogenesis, current treatments and future directions for idiopathic pulmonary fibrosis

Current Opinion in Pharmacology

Volumn 13, Issue 3, 2013, Pages 377-385

  Loomis King, Hillary ^a   Flaherty, Kevin R ^a   Moore, Bethany B ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALPHA SMOOTH MUSCLE ACTIN; AMBRISENTAN; AZATHIOPRINE; CD45 ANTIGEN; COLLAGEN; COLLAGEN TYPE 1; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DIGESTIVE TRACT SPASMOLYTIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; ETANERCEPT; EVEROLIMUS; FG 3019; GAMMA INTERFERON; NINTEDANIB; NITRIC OXIDE; OXYGEN; PIRFENIDONE; PLACEBO; PREDNISONE; PROCOLLAGEN C PROTEINASE; PROTEIN LYSINE 6 OXIDASE; PROTEIN TYROSINE KINASE INHIBITOR; SCLEROPROTEIN; SILDENAFIL; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; WARFARIN;

ANTIOXIDANT ACTIVITY; APOPTOSIS; CELL DIFFERENTIATION; CELL HYPERPLASIA; CELL PROLIFERATION; CELL TYPE; COMORBIDITY; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; EVIDENCE BASED MEDICINE; FIBROBLAST; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; GASTROESOPHAGEAL REFLUX; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG ALVEOLUS CELL TYPE 1; LUNG ALVEOLUS CELL TYPE 2; LUNG FUNCTION; LUNG TRANSPLANTATION; MACROPHAGE; MYOFIBROBLAST; NONHUMAN; OXYGEN THERAPY; PATHOGENESIS; PATIENT CARE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; PULMONARY REHABILITATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SURVIVAL RATE; VASODILATATION;

ANIMALS; COMORBIDITY; GASTROESOPHAGEAL REFLUX; HUMANS; HYPERTENSION, PULMONARY; IDIOPATHIC PULMONARY FIBROSIS;

EID: 84879117465     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2013.03.015     Document Type: Review

References (60)

1. M.P. Steele, and D.A. Schwartz Molecular mechanisms in progressive idiopathic pulmonary fibrosis Annu Rev Med 27 2012
2. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001 Am J Respir Crit Care Med 165 2002 277 304
3. T.E. King Jr., J.A. Tooze, M.I. Schwarz, K.R. Brown, and R.M. Cherniack Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model Am J Respir Crit Care Med 164 2001 1171 1181
4. G. Raghu, H.R. Collard, J.J. Egan, F.J. Martinez, J. Behr, K.K. Brown, T.V. Colby, J.F. Cordier, K.R. Flaherty, and J.A. Lasky An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management Am J Respir Crit Care Med 183 2011 788 824
5. A. Gunther, M. Korfei, P. Mahavadi, D. von der Beck, C. Ruppert, and P. Markart Unravelling the progressive pathophysiology of idiopathic pulmonary fibrosis Eur Respir Rev 21 2012 152 160
6. P.W. Noble, C.E. Barkauskas, and D. Jiang Pulmonary fibrosis: patterns and perpetrators J Clin Invest 122 2012 2756 2762
7. H. Kage, and Z. Borok EMT and interstitial lung disease: a mysterious relationship Curr Opin Pulm Med 18 2012 517 523
8. W.R. Coward, G. Saini, and G. Jenkins The pathogenesis of idiopathic pulmonary fibrosis Ther Adv Respir Dis 4 2010 367 388
9. B.B. Moore, J.E. Kolodsick, V.J. Thannickal, K. Cooke, T.A. Moore, C. Hogaboam, C.A. Wilke, and G.B. Toews CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury Am J Pathol 166 2005 675 684
10. B.B. Moore, L. Murray, A. Das, C.A. Wilke, A.B. Herrygers, and G.B. Toews The role of CCL12 in the recruitment of fibrocytes and lung fibrosis Am J Respir Cell Mol Biol 35 2006 175 181 Epub 2006 Mar 2016
11. E.F. Redente, K.M. Jacobsen, J.J. Solomon, A.R. Lara, S. Faubel, R.C. Keith, P.M. Henson, G.P. Downey, and D.W. Riches Age and sex dimorphisms contribute to the severity of bleomycin-induced lung injury and fibrosis Am J Physiol Lung Cell Mol Physiol 301 2011 L510 L518
12. P.N. Naik, J.C. Horowitz, T.A. Moore, C.A. Wilke, G.B. Toews, and B.B. Moore Pulmonary fibrosis induced by gamma-herpesvirus in aged mice is associated with increased fibroblast responsiveness to transforming growth factor-beta J Gerontol A: Biol Sci Med Sci 67 2012 714 725
13. E. Torres-Gonzalez, M. Bueno, A. Tanaka, L.T. Krug, D.S. Cheng, V.V. Polosukhin, D. Sorescu, W.E. Lawson, T.S. Blackwell, and M. Rojas Role of endoplasmic reticulum stress in age-related susceptibility to lung fibrosis Am J Respir Cell Mol Biol 46 2012 748 756
14. J.M. Englert, C.R. Kliment, L. Ramsgaard, P.S. Milutinovic, L. Crum, J.M. Tobolewski, and T.D. Oury Paradoxical function for the receptor for advanced glycation end products in mouse models of pulmonary fibrosis Int J Clin Exp Pathol 4 2011 241 254
15. V.J. Thannickal, and J.C. Horowitz Evolving concepts of apoptosis in idiopathic pulmonary fibrosis Proc Am Thorac Soc 3 2006 350 356
16. F. Liu, J.D. Mih, B.S. Shea, A.T. Kho, A.S. Sharif, A.M. Tager, and D.J. Tschumperlin Feedback amplification of fibrosis through matrix stiffening and COX-2 suppression J Cell Biol 190 2010 693 706
17. T. Maruhashi, I. Kii, M. Saito, and A. Kudo Interaction between periostin and BMP-1 promotes proteolytic activation of lysyl oxidase J Biol Chem 285 2010 13294 13303
18. P.K. Naik, P.D. Bozyk, J.K. Bentley, A.P. Popova, C.M. Birch, C.A. Wilke, C.D. Fry, E.S. White, T.H. Sisson, and N. Tayob Periostin promotes fibrosis and predicts progression in patients with Idiopathic Pulmonary Fibrosis Am J Physiol Lung Cell Mol Physiol 5 2012 5
19. M. Okamoto, T. Hoshino, Y. Kitasato, Y. Sakazaki, T. Kawayama, K. Fujimoto, K. Ohshima, H. Shiraishi, M. Uchida, and J. Ono Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias Eur Respir J 37 2011 1119 1127
20. B.D. Bringardner, C.P. Baran, T.D. Eubank, and C.B. Marsh The role of inflammation in the pathogenesis of idiopathic pulmonary fibrosis Antioxid Redox Signal 10 2008 287 301
21. L.A. Murray, R. Rosada, A.P. Moreira, A. Joshi, M.S. Kramer, D.P. Hesson, R.L. Argentieri, S. Mathai, M. Gulati, and E.L. Herzog Serum amyloid P therapeutically attenuates murine bleomycin-induced pulmonary fibrosis via its effects on macrophages PLoS ONE 5 2010 e9683
22. J.S. Lee, J.H. Ryu, B.M. Elicker, C.P. Lydell, K.D. Jones, P.J. Wolters, T.E. King Jr., and H.R. Collard Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis Am J Respir Crit Care Med 184 2011 1390 1394
23. D.A. Zisman, M. Schwarz, K.J. Anstrom, H.R. Collard, K.R. Flaherty, and G.W. Hunninghake A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis N Engl J Med 363 2010 620 628
24. American Thoracic Society Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS) Am J Respir Crit Care Med 161 2000 646 664
25. G. Raghu, W.J. Depaso, K. Cain, S.P. Hammar, C.E. Wetzel, D.F. Dreis, J. Hutchinson, N.E. Pardee, and R.H. Winterbauer Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial Am Rev Respir Dis 144 1991 291 296
26. H.R. Collard, J.H. Ryu, W.W. Douglas, M.I. Schwarz, D. Curran-Everett, T.E. King Jr., and K.K. Brown Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis Chest 125 2004 2169 2174
27. M. Demedts, J. Behr, R. Buhl, U. Costabel, R. Dekhuijzen, H.M. Jansen, W. MacNee, M. Thomeer, B. Wallaert, and F. Laurent High-dose acetylcysteine in idiopathic pulmonary fibrosis N Engl J Med 353 2005 2229 2242
28. G. Raghu, K.J. Anstrom, T.E. King Jr., J.A. Lasky, and F.J. Martinez Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis N Engl J Med 366 2012 1968 1977
29. D. Bouros, K.M. Antoniou, A. Tzouvelekis, and N.M. Siafakas Interferon-gamma 1b for the treatment of idiopathic pulmonary fibrosis Expert Opin Biol Ther 6 2006 1051 1060
30. R. Ziesche, E. Hofbauer, K. Wittmann, V. Petkov, and L.H. Block A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis N Engl J Med 341 1999 1264 1269
31. G. Raghu, K.K. Brown, W.Z. Bradford, K. Starko, P.W. Noble, D.A. Schwartz, and T.E. King Jr. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis N Engl J Med 350 2004 125 133
32. T.E. King Jr., C. Albera, W.Z. Bradford, U. Costabel, P. Hormel, L. Lancaster, P.W. Noble, S.A. Sahn, J. Szwarcberg, and M. Thomeer Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial Lancet 374 2009 222 228
33. C. Fonseca, D. Abraham, and E.A. Renzoni Endothelin in pulmonary fibrosis Am J Respir Cell Mol Biol 44 2011 1 10
34. T.E. King Jr., J. Behr, K.K. Brown, R.M. du Bois, L. Lancaster, J.A. de Andrade, G. Stahler, I. Leconte, S. Roux, and G. Raghu BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis Am J Respir Crit Care Med 177 2008 75 81
35. T.E. King Jr., K.K. Brown, G. Raghu, R.M. du Bois, D.A. Lynch, F. Martinez, D. Valeyre, I. Leconte, A. Morganti, and S. Roux BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis Am J Respir Crit Care Med 184 2011 92 99
36. J.A. Lasky, and A.R. Brody Interstitial fibrosis and growth factors Environ Health Perspect 108 2000 751 762
37. G. Raghu, K.K. Brown, U. Costabel, V. Cottin, R.M. du Bois, J.A. Lasky, M. Thomeer, J.P. Utz, R.K. Khandker, and L. McDermott Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial Am J Respir Crit Care Med 178 2008 948 955
38. C.E. Daniels, M.C. Wilkes, M. Edens, T.J. Kottom, S.J. Murphy, A.H. Limper, and E.B. Leof Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis J Clin Invest 114 2004 1308 1316
39. C.E. Daniels, J.A. Lasky, A.H. Limper, K. Mieras, E. Gabor, and D.R. Schroeder Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results Am J Respir Crit Care Med 181 2010 604 610
40. R.V. Nair, X. Huang, R. Shorthouse, B. Adams, T. Brazelton, R. Braun-Dullaeus, and R.E. Morris Antiproliferative effect of rapamycin on growth factor-stimulated human adult lung fibroblasts in vitro may explain its superior efficacy for prevention and treatment of allograft obliterative airway disease in vivo Transplant Proc 29 1997 614 615
41. N.R. Simler, D.C. Howell, R.P. Marshall, N.R. Goldsack, P.S. Hasleton, G.J. Laurent, R.C. Chambers, and J.J. Egan The rapamycin analogue SDZ RAD attenuates bleomycin-induced pulmonary fibrosis in rats Eur Respir J 19 2002 1124 1127
42. M.A. Malouf, P. Hopkins, G. Snell, and A.R. Glanville An investigator-driven study of everolimus in surgical lung biopsy confirmed idiopathic pulmonary fibrosis Respirology 16 2011 776 783
43. A. Di Sario, E. Bendia, G. Svegliati Baroni, F. Ridolfi, A. Casini, E. Ceni, S. Saccomanno, M. Marzioni, L. Trozzi, and P. Sterpetti Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production J Hepatol 37 2002 584 591
44. A. Azuma, T. Nukiwa, E. Tsuboi, M. Suga, S. Abe, K. Nakata, Y. Taguchi, S. Nagai, H. Itoh, and M. Ohi Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis Am J Respir Crit Care Med 171 2005 1040 1047
45. H. Taniguchi, M. Ebina, Y. Kondoh, T. Ogura, A. Azuma, M. Suga, Y. Taguchi, H. Takahashi, K. Nakata, and A. Sato Pirfenidone in idiopathic pulmonary fibrosis Eur Respir J 35 2010 821 829
46. P.W. Noble, C. Albera, W.Z. Bradford, U. Costabel, M.K. Glassberg, D. Kardatzke, T.E. King Jr., L. Lancaster, S.A. Sahn, and J. Szwarcberg Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials Lancet 377 2011 1760 1769
47. S.A. Antoniu Nintedanib (BIBF 1120) for IPF: a tomorrow therapy? Multidiscip Respir Med 7 2012 41
48. L.A. Murray, R.L. Argentieri, F.X. Farrell, M. Bracht, H. Sheng, B. Whitaker, H. Beck, P. Tsui, K. Cochlin, and H.L. Evanoff Hyper-responsiveness of IPF/UIP fibroblasts: interplay between TGFbeta1, IL-13 and CCL2 Int J Biochem Cell Biol 40 2008 2174 2182
49. S. Sonnylal, X. Shi-Wen, P. Leoni, K. Naff, C.S. Van Pelt, H. Nakamura, A. Leask, D. Abraham, G. Bou-Gharios, and B. de Crombrugghe Selective expression of connective tissue growth factor in fibroblasts in vivo promotes systemic tissue fibrosis Arthritis Rheum 62 2010 1523 1532
50. T. Sisson, T. Maher, I. Ajayi, J. King, P. Higgins, A. Booth, R. Sagana, S. Huang, E. White, and B. Moore Increased survivin expression contributes to apoptosis-resistance in IPF fibroblasts Adv Biosci Biotechnol 3 2012 657 664
51. P.D. Bozyk, and Moore BB Prostaglandin E2 and the pathogenesis of pulmonary fibrosis Am J Respir Cell Mol Biol 45 2011 445 452
52. C.P. Page, and D. Spina Selective PDE inhibitors as novel treatments for respiratory diseases Curr Opin Pharmacol 12 2012 275 286
53. G. Jiang, D. Madan, and G.D. Prestwich Aromatic phosphonates inhibit the lysophospholipase D activity of autotaxin Bioorg Med Chem Lett 21 2011 5098 5101
54. F.V. Castelino, J. Seiders, G. Bain, S.F. Brooks, C.D. King, J.S. Swaney, D.S. Lorrain, J. Chun, A.D. Luster, and A.M. Tager Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma Arthritis Rheum 63 1405 1405 1415
55. J.R. Crawford, D. Pilling, and R.H. Gomer FcgammaRI mediates serum amyloid P inhibition of fibrocyte differentiation J Leukoc Biol 92 2012 699 711
56. A. Montovani The chemokine system: redundancy for robust outputs Immunol Today 20 1999 254 257
57. H. Nakazato, H. Oku, S. Yamane, Y. Tsuruta, and R. Suzuki A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational level Eur J Pharmacol 446 2002 177 185
58. M.P. Keane, R.M. Strieter, J.P. Lynch 3rd, and J.A. Belperio Inflammation and angiogenesis in fibrotic lung disease Semin Respir Crit Care Med 27 2006 589 599
59. L. Richeldi, U. Costabel, M. Selman, D.S. Kim, D.M. Hansell, A.G. Nicholson, K.K. Brown, K.R. Flaherty, P.W. Noble, and G. Raghu Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis N Engl J Med 365 2011 1079 1087
60. D. Sheppard Integrin-mediated activation of latent transforming growth factor beta Cancer Metastasis Rev 24 2005 395 402